Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras

Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Pengxiang, Wong, Yu‐Ning, Armstrong, Katrina, Haas, Naomi, Subedi, Prasun, Davis‐Cerone, Margaret, Doshi, Jalpa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735783/
https://www.ncbi.nlm.nih.gov/pubmed/26645975
http://dx.doi.org/10.1002/cam4.574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735783/
https://www.ncbi.nlm.nih.gov/pubmed/26645975
http://dx.doi.org/10.1002/cam4.574

Ejemplares similares